Analysis of the gene expression for multidrug-resistance-associated protein in urogenital cancers by DNA microarrays

2001 Fiscal Year Final Research Report Summary

• Project/Area Number: 12671526
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Gifu University
• Principal Investigator: EHARA Hidetoshi Gifu University School of Medicine, lecturer, 医学部, 講師 (20252132)
• Co-Investigator(Kenkyū-buntansha): NISHINO Yoshinori Gifu University School of Medicine, lecturer, 医学部・附属病院, 助手 (90281055) ; DEGUCHI Takashi Gifu University School of Medicine, professor, 医学部, 教授 (40163935)
• Project Period (FY): 2000 – 2001
• Keywords: urogenital cancers / anticancer-resistance / DNA chip / real-time RT-PCR / chemosensitivity test

Research Abstract

To develop the new DNA microarrays superior to chemosensitivity test in urogenital cancers, we conducted a series of experiments on cell lines. Before the design of DNA chips, we synthesized a series of paired primers against genes for anticancer drug resistance associated proteins. We designed these primers to use real-time RT-PCR, simultaneously. After the fundamental experiments, we measured the expression of MDR1 mRNA by a quantitative RT-PCR (LightCycler, Roche Co.) in cancerous samples of patients undergoing surgery or biopsy (n=504), and compared with chemosensitivity test (MTT assay) in clinical specimens of uroepithelial carcinomas and renal cell carcinomas (n=43). Despite this high incidence of MDR1 expression in renal cell carcinoma no obvious association with clinicopathological parameters was found. Further, we did not find the significant associations between MOR1 expression and clinicopathological findings in prostate cancers and uroepithelial cancers. The measurement of MDR1 expression of uroepithelial cancers did not associated with the degree of resistance to anticancer drugs including doxorubicin.